Phase II Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase II
Latest Information Update: 17 Oct 2016
At a glance
- Drugs Ipilimumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 11 Oct 2016 Status changed from active, no longer recruiting to completed.
- 05 Oct 2016 Planned End Date changed from 1 Dec 2018 to 1 Dec 2017.